Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 784

Results For "IT"

10347 News Found

Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar
News | January 09, 2023

Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar

The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens


Protein found in Zebrafish can regenerate aged discs in human vertebrae
News | January 09, 2023

Protein found in Zebrafish can regenerate aged discs in human vertebrae

A study by Agharkar Research Institute (ARI), Pune, has discovered that a protein secreted from intervertebral disc cells induces disc regeneration in aged degenerated discs


KIMS invests further in Sarvejana Healthcare
News | January 07, 2023

KIMS invests further in Sarvejana Healthcare

The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare


Zydus launches Topiramate Extended-Release Capsules
Drug Approval | January 07, 2023

Zydus launches Topiramate Extended-Release Capsules

Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.


Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


Chindex Medical acquires 10 ViewRay MRIdian Systems for advanced cancer treatment
News | January 06, 2023

Chindex Medical acquires 10 ViewRay MRIdian Systems for advanced cancer treatment

Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China


PMBI launches Jan Aushadhi Chyawanprash Special
News | January 06, 2023

PMBI launches Jan Aushadhi Chyawanprash Special

Chyawanprash Special will be available at all Jan Aushadhi Kendras


Viatris acquires Oyster Point Pharma and Famy Life Sciences
Healthcare | January 05, 2023

Viatris acquires Oyster Point Pharma and Famy Life Sciences

Acquisitions have the potential to add at least $1 billion in sales by 2028